Cardiomyopathy clinical trials

Explore recruiting cardiomyopathy clinical trials.

Recruiting cardiomyopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cardiomyopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

RandomizEd trial to DEtermine the efficacy and safety of FINErenone on morbidity and mortality among heart failure patients with left ventricular ejection fraction greater than or equal to 40% hospitalized due to an episode of acute decompensated Heart Failure (REDEFINE-HF)

Poland, Czechia, Hungary, Greece, Lithuania, Germany +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

EASi-HF Reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%

Hungary, Slovakia, Czechia, Belgium, Italy, Bulgaria +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM).

Portugal, Netherlands, Germany, Spain, Czechia, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

i-Care; Quantitative-imaging in cardiac transthyretin amyloidosis

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

An Open-Label Extension Study to Assess the Long-Term Safety of Eplontersen (ION-682884) in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Belgium, Greece, Germany, Austria, Portugal, Spain +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Denmark, Italy, Hungary, Germany, Spain, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cardiomyopathy trials by city

Cardiomyopathy in Toronto Cardiomyopathy in Vancouver Cardiomyopathy in Montreal Cardiomyopathy in Calgary Cardiomyopathy in Edmonton Cardiomyopathy in Ottawa Cardiomyopathy in Winnipeg Cardiomyopathy in Quebec City Cardiomyopathy in Hamilton Cardiomyopathy in Kitchener Cardiomyopathy in London Cardiomyopathy in Halifax Cardiomyopathy in New York Cardiomyopathy in Los Angeles Cardiomyopathy in Chicago Cardiomyopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease